Danielle Gershowitz

Cooley advised HAYA Therapeutics, a biotechnology company pioneering precision RNA-guided regulatory genome-targeting therapeutics, on its $65 million Series A financing round. The round was led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly and Company, ATHOS, +ND Capital, Alexandria Venture Investments, and LifeLink Ventures, with additional support from existing investors Apollo Health Ventures, Longview Ventures (an affiliate of Broadview Ventures), 4see ventures, BERNINA Bioinvest and Schroders Capital.

Lawyers Danielle Gershowitz, Josh Seidenfeld, Amanda Gonzalez Burton, Kristine Kevorkova and Thomas Heiser led the Cooley team advising HAYA Therapeutics.

Cooley represented Clay, a company that helps go-to-market teams up-level their data enrichment and automate personalized outreach, in its $40 million preemptive Series B expansion funding at a $1.25 billion valuation.

Cooley advised Yieldstreet, a leading private market investing platform, on its acquisition of Cadre, an online real estate-focused investment platform that serves institutional and high net worth investors.

Cooley represented Runway, a developer of design tools made to bring the benefits of artificial intelligence to creative projects, on its $50 million Series C financing led by Felicis. Partner Sacha Ross led the Cooley team.

Cooley advised CinCor Pharma on its upsized $212 million initial public offering of 13,290,813 shares of common stock, which included a partial exercise of the underwriter’s option to purchase additional shares of common stock. CinCor, whose shares now trade on the Nasdaq Global Market under the symbol CINC, is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CinCor’s IPO was one of the first IPOs of 2022. Partners Ryan Sansom, Div Gupta and Courtney Thorne led the Cooley team.